ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.52
0.00%
US Tech 100
17,569.20
-0.19%
S&P 500
5,187.67
0.00%
US Dollar vs CAD
1.37285
0.00%
Bitcoin
61,051.60
-0.22%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSXV
  6. Revive Therapeutics Ltd (RVV)

  7. Revive Therapeutics Ltd (RVV) News

RVV

Revive Therapeutics (RVV)

Revive Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:TSXV:RVV
DateTimeSourceHeadlineSymbolCompany
03/29/20228:57AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
02/24/20227:35AMInvestorsHub NewsWireHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical ResearchTSXV:RVVRevive Therapeutics Ltd
02/16/20227:03AMInvestorsHub NewsWireRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver TransplantationTSXV:RVVRevive Therapeutics Ltd
01/19/20227:19AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
01/07/20227:05AMInvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
11/16/20217:00AMInvestorsHub NewsWireRevive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantTSXV:RVVRevive Therapeutics Ltd
09/22/20216:30AMInvestorsHub NewsWireRevive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETFTSXV:RVVRevive Therapeutics Ltd
09/21/202110:50AMAllPennyStocks.comETF Inclusion Sends Psychedelic Stock SoaringTSXV:RVVRevive Therapeutics Ltd
07/15/20211:47PMInvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
06/17/20217:59AMInvestorsHub NewsWireRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of PsychedelicsTSXV:RVVRevive Therapeutics Ltd
06/08/20218:12AMInvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaTSXV:RVVRevive Therapeutics Ltd
05/17/20218:48AMInvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripTSXV:RVVRevive Therapeutics Ltd
04/27/20218:51AMInvestorsHub NewsWireRevive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain InjuryTSXV:RVVRevive Therapeutics Ltd
04/22/20217:26AMInvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contTSXV:RVVRevive Therapeutics Ltd
03/19/20216:56AMInvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...ContTSXV:RVVRevive Therapeutics Ltd
02/17/20218:53AMInvestorsHub NewsWireRevive Therapeutics Acquires Unique Psilocybin AssetsTSXV:RVVRevive Therapeutics Ltd
01/18/20218:51AMInvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesTSXV:RVVRevive Therapeutics Ltd
01/14/20217:30AMInvestorsHub NewsWireRevive Therapeutics Announces Research Collaboration with North Carolina State UniversityTSXV:RVVRevive Therapeutics Ltd
12/31/20207:30AMInvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyTSXV:RVVRevive Therapeutics Ltd
12/23/20208:57AMInvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for BucillamineTSXV:RVVRevive Therapeutics Ltd
11/12/20208:00AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Oral Thin Film Product with PsilocybinTSXV:RVVRevive Therapeutics Ltd
10/20/20209:58AMInvestorsHub NewsWireRevive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic CompoundsTSXV:RVVRevive Therapeutics Ltd
09/29/20208:39AMInvestorsHub NewsWireRevive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
09/21/20209:15AMInvestorsHub NewsWireRevive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics ProgramsTSXV:RVVRevive Therapeutics Ltd
09/16/20208:59AMInvestorsHub NewsWireRevive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COV...TSXV:RVVRevive Therapeutics Ltd
09/02/20208:24AMInvestorsHub NewsWireRevive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine UseTSXV:RVVRevive Therapeutics Ltd
12/05/201411:01AMPR Newswire (Canada)Revive Therapeutics Prices and Files Final Prospectus for Equity FinancingTSXV:RVVRevive Therapeutics Ltd
06/27/20146:00AMMarketwired CanadaRevive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept StudyTSXV:RVVRevive Therapeutics Ltd
06/27/20146:00AMMarketwiredRevive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept StudyTSXV:RVVRevive Therapeutics Ltd
06/05/20146:00AMMarketwiredRevive Therapeutics Ltd. Submits Pre-IND Package to the US FDA for Its Gout Drug Candidate, REV-002TSXV:RVVRevive Therapeutics Ltd
 Showing the most relevant articles for your search:TSXV:RVV

Your Recent History

USOTC
BMXI
Brookmount Explorations (PK)
USOTC
RONN
Ronn Motor (PK)
NASDAQ
HOLO
MicroCloud Hologram
USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
KGKG
Kona Gold Beverage (PK)
USOTC
FLES
Auto Parts 4Less (PK)
USOTC
BIEL
Bioelectronics (PK)
USOTC
ILST
International Star (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
KEGS
1812 Brewing (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
TKMO
Tekumo (PK)
USOTC
PSRU
Valiant Eagle (PK)
NASDAQ
PLUG
Plug Power
USOTC
BABL
Buildablock (PK)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved